Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2014 · 10-Q
Revenue$1.13M$1.13M−9.4% vs Q3 2013 Net Income-$2.08M-$2.08MN/M vs Q3 2013 EPS Diluted-$0.05-$0.05N/M vs Q3 2013 Gross Profit$50,906−72.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$501,195N/M Free Cash Flowderived-$503,109— Margins · derivedGross margin4.5%−10.4 pt vs Q3 2013
Operating margin-87.2%−21.3 pt vs Q3 2013
Net margin-183.7%−126.5 pt vs Q3 2013
ended Mar 31, 2014 · filed May 15, 2014 · 45 d after period end